ORGANOGENESIS HOLDINGS INC. Impairment of Long-Lived Assets Held-for-use
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2026-08-06
- ORGANOGENESIS HOLDINGS INC. impairment of long-lived assets held-for-use for the quarter ending 2026-06-30 was $0.00.
- ORGANOGENESIS HOLDINGS INC. impairment of long-lived assets held-for-use for the quarter ending 2026-03-31 was $0.00.
- ORGANOGENESIS HOLDINGS INC. impairment of long-lived assets held-for-use for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. impairment of long-lived assets held-for-use for the quarter ending 2025-03-31 was $0.00.
- ORGANOGENESIS HOLDINGS INC. impairment of long-lived assets held-for-use for fiscal 2024 was $18.84M.
- ORGANOGENESIS HOLDINGS INC. impairment of long-lived assets held-for-use for fiscal 2023 was $0.00.
- ORGANOGENESIS HOLDINGS INC. impairment of long-lived assets held-for-use for fiscal 2022 was $0.00.
- ORGANOGENESIS HOLDINGS INC. impairment of long-lived assets held-for-use for fiscal 2021 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 6 month | Impairment of Long-Lived Assets Held-for-use 9 month | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $0.00 derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $0.00 derived: sum of 3 quarters · filed 2026-05-07 | $18.84M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $18.84M derived: sum of 3 quarters · filed 2026-02-26 | $18.84M 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $18.84M derived: sum of 2 quarters · filed 2025-11-06 | $18.84M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $18.84M 10-Q · filed 2025-08-07 | $18.84M 10-Q · filed 2025-08-07 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $0.00 10-K · filed 2025-02-27 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |